hiv aidslatest news & developments
What’s the best way to spend the HIV prevention budget so that the country can drive infections down as fast as possible? We take a look at what modelling data shows. (Pexels, kaboompics)

180 000 infections in 2024, 47 000 by 2045 — if SA rolls out the twice-a-year HIV prevention jab fast enough

The HIV prevention shot, lenacapavir, will be rolled out at South African clinics within the next couple of months and from 2027, the health department will also buy generics. But how best to spend the HIV prevention budget so that the country can drive infections down as fast as possible? We take a look at what the modelling data shows

Holding the purse strings: Finance Minister Enoch Godongwana presented the 2026 Budget in Cape Town on Wednesday. Photo: GCIS

Budget 2026: Between reform and reality

South Africa has been given a narrow window to turn the ship around. Whether this Budget becomes a footnote or a foundation depends on what happens next — in Cabinet, in the SOEs, in municipalities and in the daily grind of governance

Who should get SA’s first batch of lenacapavir jabs? Here’s how different scenarios compare. (Mufid Majnun/Unsplash)

SA’s first batch of LEN jabs will arrive in February. Use Bhekisisa’s dashboard to find out who should get them

Who should get what slice of the pie once the medicine is available in public clinics? And are numbers alone what would drive decisions?

To end Aids by 2043, the South African government says it could get a group of local pharmaceutical companies to make generic shots of lenacapavir from 2027 onwards. There is, however, a hitch. None of the companies that will be involved have a licence to make the jab. (Julia Koblitz/ Unsplash)

SA wants to make its own six-monthly HIV prevention jabs by 2027. But there’s a hitch

None of the companies that will be involved have a licence from the inventor of Lenacapavir, Gilead Sciences, to make the jab

Four toilets, built in 2013 by the organisation Candice Andisiwe Sehoma founded, are still flushing, although floods of raw sewage flow daily through the streets of Alexandra. (Sean Christie)

Building toilets, fighting TB: Candice Andisiwe Sehoma’s life of activism

From discontinued insulin pens to overpriced TB drugs, meet the young South African holding drug makers to account on behalf of patients

One in 10 clinics in South Africa will start to hand out a twice-a-year anti-HIV jab as early as February. The country’s medicines regulator, Sahpra, says it’s on track to announce its registration decision within the next few days, by the end of October. So who should get LEN first? (Anna-Maria van Niekerk)

The six-monthly anti-HIV jab could be in 360 clinics by February. Who should get the first doses?

The country’s medicines regulator Sahpra says it’s on track to announce its registration decision by the end of October

The Botswana Network on Ethics, Law and HIV/Aids says the crisis is not an isolated supply-chain issue but a ‘systemic failure’ that demands urgent government intervention

Botswana faces new HIV scare as shortage of medicines deepens

The Botswana Network on Ethics, Law and HIV/Aids says the crisis is not an isolated supply-chain issue but a ‘systemic failure’ that demands urgent government intervention

According to a survey, 85% of managers reported that their clinics faced staffing shortages, though only one in five blamed these on the US President’s Emergency Plan For Aids Relief cuts

Clinics short-staffed after Pepfar funding cuts

According to a survey, 85% of managers reported that their clinics faced staffing shortages, though only one in five blamed these on the US President’s Emergency Plan For Aids Relief cuts

Long shot?: In April next year, South Africa plans to start rolling out an anti-HIV jab, taken only twice a year, that could end Aids in the country within 14 to 18 years. But is our public health system equipped to keep track of millions, who are on the shot? (Unsplash)

The six-monthly anti-HIV jab is coming. But can SA keep track of millions of users?

The shot, called Lenacapavir, has a 100% success rate in preventing young women from getting HIV through sex

Two Indian generic drugmakers — Hetero and Dr Reddy’s — will be funded by the Gates Foundation and Unitaid, respectively, to produce and sell the twice-a-year anti-HIV shot around R692 per person per year. (Anna-Maria van Niekerk)

Two drugmakers will sell the 6-monthly anti-HIV jab for the price of the daily prevention pill

Hetero and Dr Reddy’s will be funded by the Gates Foundation and Unitaid to produce and sell the twice-a-year anti-HIV shot around R692 per person a year

Nompilo Mdluli — in brown jacket — and Simphiwe Matsebula — in black jersey are worried that the Pepfar pause on HIV services in eSwatini could negatively affect the lives of people living with HIV especially daily access to antiretroviral treatment which helps keep their virus under control.

People living with HIV in fear as impact of donor funding cuts begin to show in eSwatini

HIV prevention services have been heavily affected by the pause on the US President’s Emergency Plan for Aids in the country, with remote mobile clinics that served hard-to-reach people now closed

Sign outside the offices of an organisation in Mozambique that was defunded by USAid. Photos: Jesse Copelyn

Mozambican children die after US funding cuts: Who bears responsibility?

The least the Trump administration could have done was provide ample warning that it was going to cut aid

Doctors will need to pay attention not only to a patient’s physical health but also the person’s emotional, social and psychospiritual aspects.

National Health Insurance system will mean little if we don’t offer the right kind of care

Although the NHI offers much-needed reform, it must find a new way to care for patients – an approach that treats people emotionally, physically, socially, psychologically and spiritually

Conventional and complementary healthcare professionals need to work together

An inter-referral system between conventional and complementary medical practitioners is essential to giving patients optimal care in our diverse society

Foreign aid has been the backbone of Africa’s HIV/Aids response but now the continent must take control of its health future.

A letter to the African Union and the continent’s governments

Aid dependency in the fight against HIV/Aids is not sustainable; Africa must own its health future. With political will, nothing is impossible

Local pharmaceutical production would help insulation against external shocks, which hurts vulnerable people the most.

US aid cuts: Africa must make its own medicine

Donald Trump’s funding freeze underlines that South Africa needs to prioritise the development of its pharmaceutical manufacturing sector

‘Without continued support, patients may miss treatment, HIV infection rates may rise, and ultimately, more lives could be lost.’ Photo: Reuters

The endgame to HIV/Aids

The United States’ shutdown of HIV/Aids funding may harm global Aids programmes irreparably, jeopardising millions of lives and putting HIV prevention at risk

Finance Minister Enoch Godongwana did not announce a budget allocation to plug the gap created by the termination of USAid funding to HIV/Aids organisations (Photo by Luke Dray/Getty Images)

No allocations for Pepfar in health budget

The recent termination of USAid to HIV/Aids and TB organisations in South Africa was a bone of contention in the 2025 budget

The continent must come up with long-term solutions to wean countries off aid dependency. Photo: Guillem Sartorio/AFP

How Africa can recover from the disease of aid dependency

In a changing world order, the continent must make urgent moves to wean itself off handouts

A volunteer demonstrates an HIV screening test. (File photo)

Trump’s funding cuts hit HIV, GBV services hard

The US president’s cutting of financial support has cut life-saving treatment for many in SA